Jada Bascom Foundation
All conditions

Inherited metabolic disorders

Mucolipidosis II alpha/beta

Also called: ML II · MLII · GNPTAB-related mucolipidosis II · I-cell disease · Mucolipidosis type II · Inclusion-cell disease

What a donor has to do with this

A transplant is not a standard part of treating this condition. It is used rarely, in particular situations, and most people diagnosed with it will not have one.

This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.

This page is not written out in full yet

We have not written this condition out in full yet. What is on this page — how a donor fits in, who it affects, and the sources behind that — is researched and linked, but the plain-English explanation of the condition itself is still to come.

What the evidence says

Who it affects
Typical onset/diagnosis: abnormalities are often evident prenatally or at birth in either sex. Evidence: U.S. NIH GARD synthesis (updated 2026); no markedly enriched population was identified in the opened sources.
Treatments other than a transplant
Multidisciplinary cardiopulmonary, orthopedic, nutritional, and palliative care — standard noncurative management — multiple regions — No approved disease-modifying product.
If a transplant is used, the cells come from
bone marrow: not separately reported in the opened cohort metadata; mobilized peripheral blood stem cells: not separately reported in the opened cohort metadata; umbilical cord blood: not separately reported in the opened cohort metadata; dominance: not reported in the opened cohort metadata
How often the donor was unrelated
Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.

Where this gets complicated

Registry and case reports have not established clear survival or neurodevelopmental benefit, and transplant-related risk is substantial.; MLII alpha/beta must not be merged with the milder MLIII alpha/beta or MLIII gamma disorders.

Written for transplant clinicians, not for patients. We quote it so you can see what the guidance actually says:
“we describe the combined international experience in the use of HSCT for MLII”

It describes what teams consider in general. It cannot say what applies to any one person. Read the source.

Registries need people

An unrelated donor is not a usual part of treating this condition. Registering still matters, for the many conditions where it is.

Joining a registry is a cheek swab and a short health form. You are not matched to a condition — you are matched to a person, and it could be someone with any of the conditions in this library. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.

Find your registry

Related conditions

Others in inherited metabolic disorders. They are genuinely different diseases with different treatments — the group name is not a diagnosis.

Where this came from